Adage Capital Partners GP L.L.C. Grows Stake in Surrozen, Inc. $SRZN

Adage Capital Partners GP L.L.C. lifted its position in Surrozen, Inc. (NASDAQ:SRZN - Free Report) by 37.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 88,653 shares of the company's stock after purchasing an additional 24,000 shares during the quarter. Adage Capital Partners GP L.L.C. owned about 2.70% of Surrozen worth $1,034,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in SRZN. Heights Capital Management Inc. purchased a new position in Surrozen in the first quarter worth about $524,000. Trustees of Columbia University in the City of New York purchased a new position in shares of Surrozen during the fourth quarter valued at approximately $688,000. Stonepine Capital Management LLC boosted its position in shares of Surrozen by 24.7% during the fourth quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company's stock valued at $1,969,000 after buying an additional 27,200 shares during the period. Driehaus Capital Management LLC purchased a new position in shares of Surrozen during the first quarter valued at approximately $2,390,000. Finally, Nantahala Capital Management LLC boosted its position in shares of Surrozen by 17.1% during the first quarter. Nantahala Capital Management LLC now owns 229,527 shares of the company's stock valued at $2,676,000 after buying an additional 33,504 shares during the period. 66.57% of the stock is owned by institutional investors.

Surrozen Trading Down 0.9%

Shares of Surrozen stock traded down $0.11 on Wednesday, hitting $11.60. 5,796 shares of the company traded hands, compared to its average volume of 15,610. The stock's 50 day moving average price is $10.16 and its 200-day moving average price is $9.91. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $18.17. The company has a market cap of $99.37 million, a PE ratio of -0.80 and a beta of 0.62.

Surrozen (NASDAQ:SRZN - Get Free Report) last posted its quarterly earnings results on Friday, August 8th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.09. Surrozen had a negative net margin of 274.42% and a negative return on equity of 545.43%. The firm had revenue of $0.98 million during the quarter. As a group, research analysts anticipate that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Surrozen Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.